Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone
Title:
Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone
Author:
Nicolini, Franck E. Hayette, Sandrine Legros, Laurence Rousselot, Philippe Maloisel, Frédéric Tulliez, Michel Guerci, Agnès Charbonnier, Aude Prébet, Thomas Rigal-Huguet, Françoise Chabane, Kaddour Magaud, Jean-Pierre Paillet, Carole Pivot, Christine Michallet, Mauricette